- Avenue Therapeutics Inc ATXI acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc FBIO.
- Founded in December 2019, Baergic Bio focuses on developing a pharmaceutical product for CNS disorders.
- Its pipeline currently includes a single compound, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator, which was in-licensed from AstraZeneca Plc AZN.
- Preclinical data have substantiated the efficacy of BAER-101 as a novel anxiolytic and antiepileptic.
- Benzodiazepines interact non-selectively with GABA-A receptor (GABA-AR) subunits, especially the α1 subunit.
- By selectively targeting the α2/3 subunits of the GABA-A receptor, BAER-101 may spare the adverse effects associated with benzodiazepine use. Consistent with its selectivity over α1-preferring GABA-ARs, BAER-101 may have a reduced propensity to produce sedation and memory impairment.
- To date, clinical experience in over 700 patients has shown that BAER-101 is safe and side effects were mild to moderate.
- Price Action: ATXI shares are up 1.80% at $1.70 on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.